Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > CD8+ TiLs and T-cell exhaustion
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5861)
•••
Comment by Noteableon May 31, 2024 1:34pm
97 Views
Post# 36066645

RE:CD8+ TiLs and T-cell exhaustion

RE:CD8+ TiLs and T-cell exhaustionWith the exception of PD-L1 and TMB, there are no predictive biomarkers to guide immune checkpoint inhibitor treatment decisions in advanced or metastatic breast cancer, according to a paper that was pressented at ESMO 2024. This may have been the case UP UNTIL NOW with clinical evidence that shows ONCY's pelareorep is able to drive biomarkers that enhance exisiting and new CD8+ -TiLs complex T cells in the blood and TME in advance of immune checkpoint inhibition. 

This data will appear in an ASCO 2024 poster presention given by ONCY and entitled: Pelareorep driven blood TIL expansion in patients with pancreatic, breast and colon cancer.

https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-upcoming-presentations-at-the-american-society-of-clinical-oncology-annual-meeting/

https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00414-4/fulltext

https://www.esmoopen.com/article/S2059-7029(24)00732-4/fulltext



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities